Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy.
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy.

Karacin, Cengiz;Eren, Tulay;Zeynelgil, Esra;Imamoglu, Goksen Inanc;Altinbas, Mustafa;Karadag, Ibrahim;Basal, Fatma Bugdayci;Bilgetekin, Irem;Sutcuoglu, Osman;Yazici, Ozan;Ozdemir, Nuriye;Ozet, Ahmet;Yildiz, Yesim;Esen, Selin Akturk;Ucar, Gokhan;Uncu, Dogan;Dinc, Bedia;Aykan, Musa Baris;Erturk, İsmail;Karadurmus, Nuri;Civelek, Burak;Çelik, İsmail;Ergun, Yakup;Dogan, Mutlu;Oksuzoglu, Omur Berna;
Future oncology (London, England) 2021 Vol. 17 pp. 4447-4456
125
karacin2021immunogenicityfuture

Abstract

To evaluate the immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. This multicenter, prospective, observational study was conducted with 47 patients receiving active systemic therapy for cancer. CoronaVac was administered as two doses (3 μg/day) on days 0 and 28. Antibody level higher than 1 IU/ml was defined as 'immunogenicity.' The immunogenicity rate was 63.8% (30/47) in the entire patient group, 59.5% (25/42) in those receiving at least one cytotoxic drug and 100% (five of five) in those receiving monoclonal antibody or immunotherapy alone. Age was an independent predictive factor for immunogenicity (odds ratio: 0.830; p = 0.043). More than half of cancer patients receiving active systemic therapy developed immunogenicity.

Keywords

Cancer Chemotherapy safety Monoclonal antibody vaccine immunotherapy immunogenicity tumors covid-19

Access

DOI:
10.2217/fon-2021-0597

Citation

ID: 276316
Ref Key: karacin2021immunogenicityfuture
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
276316
Unique Identifier:
10.2217/fon-2021-0597
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet
Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store